Commodore Capital LP Sells 448,289 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Commodore Capital LP reduced its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 13.6% in the 3rd quarter, Holdings Channel reports. The firm owned 2,850,000 shares of the company’s stock after selling 448,289 shares during the quarter. Centessa Pharmaceuticals comprises approximately 3.4% of Commodore Capital LP’s investment portfolio, making the stock its 11th biggest position. Commodore Capital LP’s holdings in Centessa Pharmaceuticals were worth $69,112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Millennium Management LLC boosted its position in shares of Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after acquiring an additional 210,737 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at approximately $2,176,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter worth approximately $218,000. Geode Capital Management LLC lifted its position in shares of Centessa Pharmaceuticals by 44.7% during the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock worth $1,149,000 after buying an additional 26,994 shares during the period. Finally, Candriam S.C.A. acquired a new stake in Centessa Pharmaceuticals in the 2nd quarter valued at $4,568,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analysts Set New Price Targets

CNTA has been the subject of a number of analyst reports. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a report on Friday, January 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. B. Riley Financial raised their price objective on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, December 1st. TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Finally, Wolfe Research began coverage on Centessa Pharmaceuticals in a report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $39.80.

Centessa Pharmaceuticals Trading Down 3.3%

CNTA stock opened at $26.33 on Friday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $30.58. The company has a market cap of $3.85 billion, a P/E ratio of -14.39 and a beta of 1.55. The business has a fifty day moving average of $24.69 and a 200-day moving average of $24.29.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the sale, the insider directly owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. The trade was a 40.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Karen M. Anderson sold 120,029 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider directly owned 62,085 shares in the company, valued at $1,629,731.25. This trade represents a 65.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 233,186 shares of company stock worth $6,082,890 over the last three months. 7.09% of the stock is currently owned by company insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.